This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
After more than 15 years, the battle between the Canada Revenue Agency and Glaxo Canada over the transfer price for ranitidine—the active pharmaceutical ingredient used to make the branded, anti-ulcer drug Zantac—finally reached the Supreme Court of Canada (SCC) last month.
In this Insights, our transfer pricing consultants reflect on significant transfer pricing developments in 2024 and anticipate trends for 2025. We begin with...
Congratulations to Rebel Curd and David Kemp for their recent recognition as “highly regarded” leaders in International Tax Review’s (ITR) 2025 World Tax...
CRA is a proud sponsor of the event bringing together global transfer pricing leaders to understand the direction of international tax policy reform, benchmark...
David Kemp is on the planning committee of the conference and moderates the session titled “Industry Panel: Pragmatic Approaches to Transfer Pricing.” There...
